Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
APL-501 · 1 trial · 4 indications
Adverse events, serious adverse events, dose limiting toxicities according to the National Cancer Institute (NCI) Terminology Criteria for Adverse Events (CTCAE v4.03)
| Arm | Type | Description |
|---|---|---|
| Single-Arm | EXPERIMENTAL | APL-501 |
| Name | Type | Description |
|---|---|---|
| APL-501 | DRUG | Subjects will be assigned to a dose level in the order of study entry. Treatment includes a minimum of four 28-day cycles at three planned dose levels (1, 3, and 10 mg/kg). In the Dose Escalation Segment, each treatment cycle is comprised of 2 doses of study drug administered on Days 1 and 15 of a 28-day cycle. In the Cohort Extension, the treatment cycle will consist of 2 doses of study drug administered on Days 1 and 15 of a 28-day cycle. In Dose and Disease Expansion, the treatment cycle will consist of 2 doses of study drug (non-weight based dosing of 400 mg) administered on Days 1 and 15 of a 28-day cycle. |
Major Inclusion Criteria: • Able to understand and comply with study procedures, understand the risks involved, and provide written informed consent. Dose Escalation: * Histologically and / or cytological confirmed solid tumors: colorectal, endometrial, gastric including, gastroesophageal junctio...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
APL-501 is an investigational small molecule being developed for the treatment of solid tumors. It is being studied in patients with advanced or relapsed/recurrent solid tumors, including those with microsatellite instability, mismatch repair deficiency, and cancer of unknown primary site. The drug is currently in Phase 1 clinical development.
APL-501 is being developed by Apollomics Inc., a biopharmaceutical company. Apollomics is publicly traded under the ticker symbol APLM. The company is conducting clinical trials to evaluate the safety and efficacy of APL-501 in patients with solid tumors.
APL-501 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study of APL-501 has been completed, and the drug remains in early-stage clinical development for the treatment of solid tumors.
APL-501 has been studied in a Phase 1 clinical trial with the identifier NCT03053466. This trial, titled 'APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors,' enrolled 30 participants in Australia. The study has been completed and was an uncontrolled, non-randomized trial.
APL-501 is a small molecule therapeutic. Its specific molecular target has not been disclosed in available information. The drug is being investigated for its potential to treat solid tumors, including those with microsatellite instability and mismatch repair deficiency.